Literature DB >> 31524115

Twenty years of experience in revision cochlear implant surgery: signs that indicate the need for revision surgery to audiologists.

M O Batuk1, B C Cinar1, M Yarali1, M D Bajin2, G Sennaroglu1, L Sennaroglu2.   

Abstract

OBJECTIVE: To report device failures, audiological signs and other reasons for revision cochlear implant surgery, and discuss indications for revision surgery.
METHODS: Revision procedures between November 1997 and August 2017 were retrospectively analysed. Over 20 years, 2181 cochlear implant operations were performed, and 114 patients underwent 127 revision operations.
RESULTS: The revision rate was 4.67 per cent. The full insertion rate for revision cochlear implant surgery was 88.2 per cent. The most frequent reasons for revision surgery were: device failure (59 per cent), wound breakdown (9.4 per cent) and electrode malposition (8.7 per cent). The device failure rate was: 2.78 per cent for Advanced Bionics, 1.82 per cent for Cochlear and 5.25 per cent for Med-El systems. The number of active electrodes was significantly increased only for Med-El devices after revision surgery. The most common complaints among 61 patients were: gradually decreased auditory performance, sudden internal device shutdown and headaches.
CONCLUSION: The most common reason for revision surgery was device failure. Patients should be evaluated for device failure in cases of: no hearing despite appropriate follow up, side effects such as facial nerve stimulation, and rejection of speech processor use in paediatrics. After revision surgery, most patients have successful outcomes.

Entities:  

Keywords:  Cochlear Implantation; Hearing Loss; Reimplantation; Reoperation; Surgery

Year:  2019        PMID: 31524115     DOI: 10.1017/S0022215119001919

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  1 in total

Review 1.  Research Status and Future Development of Cochlear Reimplantation.

Authors:  Xinyi Yao; Haotian Liu; Jinyuan Si; Xiuyong Ding; Yu Zhao; Yun Zheng
Journal:  Front Neurosci       Date:  2022-03-21       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.